Video

Dr. Garon on the KEYNOTE-001 Study in NSCLC

Edward B. Garon, MD, MS, discusses the KEYNOTE-001 study, which examined the 5-year long-term overall survival in patients with non–small cell lung cancer treated with pembrolizumab.

Edward B. Garon, MD, MS, associate professor of medicine, David Geffen School of Medicine, University of California, Los Angeles, discusses the KEYNOTE-001 study, which examined the 5-year long-term overall survival (OS) in patients with non—small cell lung cancer (NSCLC) treated with pembrolizumab (Keytruda).

The KEYNOTE-001 study was the original study of pembrolizumab, according to Garon. However, it was unlike other first-in-human studies because it enrolled over 1000 patients and led to the initial approvals in melanoma and NSCLC, explained Garon. It also led to approval for an assay to look at PD-L1 expression.

The study showed that the 5-year OS rate was 23.2% in treatment-naïve patients and 15.5% in previously treated patients. The study also showed that the clinical benefit appeared to correlate well with PD-L1 expression, particularly with the best outcomes being amongst patients who had PD-L1 expression in at least half of their tumor cells, according to Garon. The 5-year OS rate in patients with high levels of PD-L1 expression was 29.6% in treatment-naïve patients and 25% in previously treated patients.

Related Videos
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD